A microcomputer-based system using admission characteristics predicted 30-day mortality for Medicare patients with stroke, pneumonia, MI, and CHF with a cross-validated R2 of 0.14 to 0.25.
Observational (n=5,888)
Yes
Can a microcomputer-based system using admission characteristics accurately predict 30-day mortality in Medicare patients with stroke, pneumonia, myocardial infarction, or congestive heart failure?
A microcomputer-based system using admission characteristics can predict 30-day mortality with a cross-validated R2 of 0.14 to 0.25 in Medicare patients with common acute conditions.
Effect estimate: R2 0.14 to 0.25
We created a microcomputer-based system that uses characteristics of the patient at admission to predict death within 30 days of hospital admission for Medicare patients with stroke, pneumonia, myocardial infarction, and congestive heart failure. These conditions account for 13% of discharges and 31% of 30-day mortality for Medicare patients over 64 years of age. The system was calibrated on a stratified, random sample of 5888 discharges (about 1470 for each condition) from seven states, with stratification by hospital type to make the sample nationally representative. The predictors must be specially abstracted from the medical record. The cross-validated R2 for predictions is 0.14 to 0.25, which is better than the values for other systems for which we have data. Risk-adjusted predicted group mortality rates may be useful in interpreting information on unadjusted mortality rates, and patient-specific predictions may be useful in identifying unexpected deaths for clinical review.
Jennifer Daley (1988) conducted an observational in stroke, pneumonia, acute myocardial infarction, and congestive heart failure (n=5,888). microcomputer-based mortality prediction system vs. other systems was evaluated on death within 30 days of hospital admission (R2 0.14 to 0.25). A microcomputer-based system using admission characteristics predicted 30-day mortality for Medicare patients with stroke, pneumonia, MI, and CHF with a cross-validated R2 of 0.14 to 0.25.